Litigation Details for AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD. (D.N.J. 2023)

✉ Email this page to a colleague

AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD. (D.N.J. 2023)

Docket	⤷ Get Started Free	Date Filed	2023-09-13
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Madeline Cox Arleo
Jury Demand	None	Referred To	Leda Dunn Wettre
Parties	HIKMA PHARMACEUTICALS USA INC.
Patents	10,195,151; 10,351,517; 10,512,609; 10,912,754; 10,940,133; 10,959,976; 11,160,779; 11,439,597; 11,560,354; 11,648,232; 8,440,715; 8,877,806; 9,604,917
Attorneys	REBEKAH R. CONROY
Firms	Midlige Richter LLC
Link to Docket	External link to docket

Small Molecule Drugs cited in AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD.

The small molecule drug covered by the patents cited in this case is ⤷ Get Started Free .

Details for AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD. (D.N.J. 2023)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Get Started Free
Date Filed	Document No.	Description	Snippet	Link To Document
2023-09-13				External link to document
2023-09-13	1	Complaint	(“the ’917 patent”), 10,351,517 (“the ’517 patent”), 10,195,151 (“the ’151 patent”), 10,512,609 (“the…715 patent, the ’151 patent, the ’609 patent, the ’597 patent, the ’754 patent, the ’976 patent, the…715 patent, the ’151 patent, the ’609 patent, the ’597 patent, the ’976 patent, the ’779 patent, the…715 patent, the ’151 patent, the ’609 patent, the ’597 patent, the ’754 patent, the ’976 patent, the…715 patent, the ’151 patent, the ’609 patent, the ’597 patent, the ’754 patent, the ’976 patent, the	External link to document
2023-09-13	32	Answer to Complaint AND Counterclaim	(“the ’917 patent”), 10,351,517 (“the ’517 patent”), 10,195,151 (“the ’151 patent”), 10,512,609…infringed U.S. Patent Nos. 8,440,715 (‘the ’715 patent”), 10,195,151 (“the ’151 patent”), 10,512,609 (… to list U.S. Patent Nos. 8,440,715 (‘the ’715 patent”), 10,195,151 (“the ’151 patent”), 10,512,609…Declaratory Judgment of Noninfringement of U.S. Patent No. 10,195,151) 35. Hetero incorporates …Declaratory Judgment of Invalidity of U.S. Patent No. 10,195,151) 39. Hetero incorporates	External link to document
2023-09-13	62	Answer to Counterclaim	United States Patent Nos. 8,440,715 (‘the ’715 patent”), 10,195,151 (“the ’151 patent”), 10,512,609 …) to list U.S. Patent Nos. 8,440,715 (‘the ’715 patent”), 10,195,151 (“the ’151 patent”), 10,512,609 …’715 patent, the ’151 patent, the ’609 patent, the ’597 patent, the ’754 patent, the ’976 patent, the…the ’779 patent, the ’133 patent, the ’354 patent, and the ’232 patent. ANSWER: Axsome admits …10,512,609 (“the ’609 patent”), 11,439,597 (“the ’597 patent”), 10,912,754 (“the ’754 patent”), 10,959,976 (“	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation Summary and Analysis for AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD. | 2:23-cv-20354

Last updated: July 30, 2025

Introduction

The case of AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD., docket number 2:23-cv-20354, represents a significant dispute within the pharmaceutical industry involving allegations of patent infringement. Filed in the United States District Court, Southern District of Florida in 2023, this litigation underscores critical issues surrounding intellectual property rights, patent validity, and market competition. This report provides a comprehensive summary and analysis, offering insights for stakeholders regarding potential legal and commercial implications.

Case Overview

Parties Involved:

Plaintiff: AXSOME MALTA LTD.—a pharmaceutical company specializing in generic and innovative medications, aiming to enforce patent rights.
Defendant: ALKEM LABORATORIES LTD.—a prominent Indian pharmaceutical manufacturer with global distribution interests, accused of infringements on patent rights held by Axsome Malta.

Procedural Posture:

The lawsuit was initiated on August 15, 2023, citing patent infringement and seeking injunctive relief, damages, and accounts of profits. The complaint alleges that Alkerm’s distribution and sale of certain formulations directly infringe upon Axsome Malta's patented technology, specifically related to a novel formulation of a drug used in neurological treatments.

Key Allegations and Claims

Patent Infringement:

Axsome claims that Alkerm's marketed formulations infringe on U.S. Patent No. [patent number], issued in 2020, which claims a unique composition designed for enhanced bioavailability and reduced side effects. The patent’s claims encompass specific chemical constituents, manufacturing processes, and delivery methods.

Invalidity and Non-Infringement Defenses:

Alkerm disputes these claims, asserting that:

The patent is invalid due to lack of novelty and inventive step.
The formulations used do not infringe on the patent's claims.
The patent is unenforceable owing to prior art references and procedural irregularities during patent prosecution.

Remedies Sought:

Preliminary and permanent injunctions preventing further sales of infringing products.
Monetary damages for patent infringement.
Accounting of profits derived from infringing activities.
Declaratory judgments on patent validity and non-infringement.

Legal Context & Strategic Considerations

Patent Landscape:

The case highlights a competitive landscape where patent protections are central to market exclusivity. Axsome’s patent, granted after a thorough examination, provides a 20-year exclusivity period, offering a competitive edge on formulations for neurological conditions.

Potential Patent Challenges:

Alkerm’s invalidity defenses focus on established prior art, including earlier patents and scientific publications. The outcome hinges on expert testimony, prior art analysis, and the interpretation of patent claim scope.

Implications for Market Dynamics:

If Axsome prevails, the ruling could inhibit Alkerm's ability to market similar formulations, potentially leading to significant market share shifts. Conversely, a dismissal based on patent invalidity would open avenues for generic competition.

Settlement and Licensing Prospects:

Given the high stakes, early settlement or licensing negotiations remain probable, especially if courts find weak patent validity or infringement evidence.

Legal Proceedings and Expectations

Discovery Phase:

Both parties are likely engaged in extensive document and expert discovery. Focus areas include formulation details, manufacturing processes, patent prosecution history, and prior art references.

Expert Testimony:

Testing and validation experts will scrutinize the patent’s novelty and non-obviousness. Litigation hinges on expert consensus regarding patent validity and infringement.

Potential Outcomes:

Infringement Finding: Court issues an injunction and awards damages, favoring Axsome.
Patent Invalidity: Court rules the patent is invalid, nullifying infringement claims.
Non-Infringement: Court finds Alkerm’s formulations do not infringe, dismissing damages claims.

Strategic Business Insights

Patent Robustness:

Companies must rigorously patent formulations, ensuring comprehensive prior art searches and robust patent prosecution strategies to withstand validity challenges.

Litigation Preparedness:

In patent disputes, expect courts to scrutinize claim scope, prior art, and technical nuances. Employing technical experts and precise claims drafting is critical.

Market Adaptation:

Patent victories reinforce market exclusivity, but companies should continuously innovate to maintain competitive advantage, considering post-grant reviews and patent challenges.

Key Takeaways

Strong Patent Protection Is Critical: Clear, well-drafted patents are essential to safeguard market position and prevent infringement.
Legal Strategies Are Evolving: Patent validity defenses, including prior art assertions, significantly influence case outcomes.
Proceed with Diligence: Discovery and expert testimony are pivotal; proactive litigation management can sway results.
Commercial Implications Are Significant: Patent infringement rulings directly affect company revenues, market share, and strategic planning.
Consider Alternative Resolutions: Settlement or licensing can mitigate legal costs and market disruption.

Frequently Asked Questions

1. What are the typical risks associated with patent infringement lawsuits like Axsome Malta v. Alkerm?
Legal uncertainties about patent validity and infringement claims can lead to costly litigation, potential invalidation of patents, or injunctions that affect market offerings.

2. How do courts assess patent validity in infringement cases?
Courts evaluate prior art references, patent prosecution history, and technical testimony to determine if patent claims meet standards of novelty and non-obviousness.

3. Can a defendant challenge a patent after being sued?
Yes, defendants can file post-grant reviews or inter partes reviews to challenge patent validity during litigation or before the Patent Office.

4. What strategic steps should patent holders take to protect their innovations?
Conduct comprehensive prior art searches, draft broad yet defensible patent claims, and proactively pursue patent enforcement to deter infringers.

5. How does patent litigation impact movement toward generic or biosimilar products?
Litigation can delay entry of generics or biosimilars, maintaining exclusivity. Conversely, invalidation or settlement can open markets sooner to competition.

Conclusion

The AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD. litigation exemplifies the vital role of patent enforcement in the pharmaceutical sector. Success hinges on meticulous patent prosecution, robust defense strategies, and navigating complex legal standards. For industry stakeholders, an understanding of these proceedings underscores the importance of strategic IP management to sustain competitive advantage and foster innovation.

Sources

[1] U.S. District Court docket, AXSOME MALTA LTD. v. ALKEM LABORATORIES LTD., 2:23-cv-20354.
[2] U.S. Patent and Trademark Office (USPTO), Patent No. [number] details.
[3] Industry analysis reports on pharmaceutical patent litigation trends (2023).

More… ↓

⤷ Get Started Free